nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—Peripheral ischaemia—Varenicline—nicotine dependence	0.0321	0.0336	CcSEcCtD
Betaxolol—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0302	0.0316	CcSEcCtD
Betaxolol—Sleep disturbance—Varenicline—nicotine dependence	0.0209	0.0218	CcSEcCtD
Betaxolol—Psoriasis—Varenicline—nicotine dependence	0.0186	0.0195	CcSEcCtD
Betaxolol—Menstrual disorder—Varenicline—nicotine dependence	0.0172	0.018	CcSEcCtD
Betaxolol—Thrombosis—Varenicline—nicotine dependence	0.0165	0.0173	CcSEcCtD
Betaxolol—Hyperlipidaemia—Varenicline—nicotine dependence	0.0162	0.017	CcSEcCtD
Betaxolol—Scotoma—Varenicline—nicotine dependence	0.0154	0.0161	CcSEcCtD
Betaxolol—Rhinorrhoea—Varenicline—nicotine dependence	0.0144	0.0151	CcSEcCtD
Betaxolol—Eye irritation—Varenicline—nicotine dependence	0.0137	0.0143	CcSEcCtD
Betaxolol—Disturbance in attention—Varenicline—nicotine dependence	0.0135	0.0141	CcSEcCtD
Betaxolol—Accidental injury—Varenicline—nicotine dependence	0.0132	0.0138	CcSEcCtD
Betaxolol—Thinking abnormal—Varenicline—nicotine dependence	0.0128	0.0134	CcSEcCtD
Betaxolol—Lacrimation increased—Varenicline—nicotine dependence	0.0127	0.0133	CcSEcCtD
Betaxolol—Leukocytosis—Varenicline—nicotine dependence	0.0125	0.013	CcSEcCtD
Betaxolol—Abnormal dreams—Varenicline—nicotine dependence	0.0116	0.0121	CcSEcCtD
Betaxolol—Hyperkalaemia—Varenicline—nicotine dependence	0.0115	0.012	CcSEcCtD
Betaxolol—Salivary hypersecretion—Varenicline—nicotine dependence	0.0114	0.0119	CcSEcCtD
Betaxolol—Nightmare—Varenicline—nicotine dependence	0.0113	0.0118	CcSEcCtD
Betaxolol—Photophobia—Varenicline—nicotine dependence	0.011	0.0115	CcSEcCtD
Betaxolol—Dry eye—Varenicline—nicotine dependence	0.0108	0.0113	CcSEcCtD
Betaxolol—Mouth ulceration—Varenicline—nicotine dependence	0.0106	0.0111	CcSEcCtD
Betaxolol—Hypertonia—Varenicline—nicotine dependence	0.0103	0.0107	CcSEcCtD
Betaxolol—Mental disability—Varenicline—nicotine dependence	0.0102	0.0106	CcSEcCtD
Betaxolol—Lymphadenopathy—Varenicline—nicotine dependence	0.00996	0.0104	CcSEcCtD
Betaxolol—Sleep disorder—Varenicline—nicotine dependence	0.00982	0.0103	CcSEcCtD
Betaxolol—Diabetes mellitus—Varenicline—nicotine dependence	0.00977	0.0102	CcSEcCtD
Betaxolol—Deafness—Varenicline—nicotine dependence	0.0095	0.00993	CcSEcCtD
Betaxolol—Disorientation—Varenicline—nicotine dependence	0.0095	0.00993	CcSEcCtD
Betaxolol—Eczema—Varenicline—nicotine dependence	0.00945	0.00989	CcSEcCtD
Betaxolol—Eye pain—Varenicline—nicotine dependence	0.00941	0.00984	CcSEcCtD
Betaxolol—Injury—Varenicline—nicotine dependence	0.00924	0.00967	CcSEcCtD
Betaxolol—Libido decreased—Varenicline—nicotine dependence	0.00916	0.00958	CcSEcCtD
Betaxolol—Increased appetite—Varenicline—nicotine dependence	0.00904	0.00946	CcSEcCtD
Betaxolol—Amnesia—Varenicline—nicotine dependence	0.00904	0.00946	CcSEcCtD
Betaxolol—Thirst—Varenicline—nicotine dependence	0.00893	0.00934	CcSEcCtD
Betaxolol—Arthritis—Varenicline—nicotine dependence	0.00874	0.00914	CcSEcCtD
Betaxolol—Hypoglycaemia—Varenicline—nicotine dependence	0.00871	0.00911	CcSEcCtD
Betaxolol—Lethargy—Varenicline—nicotine dependence	0.00867	0.00907	CcSEcCtD
Betaxolol—Osteoarthritis—Varenicline—nicotine dependence	0.0085	0.00889	CcSEcCtD
Betaxolol—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00843	0.00882	CcSEcCtD
Betaxolol—Affect lability—Varenicline—nicotine dependence	0.00836	0.00875	CcSEcCtD
Betaxolol—Psychotic disorder—Varenicline—nicotine dependence	0.0083	0.00868	CcSEcCtD
Betaxolol—Mood swings—Varenicline—nicotine dependence	0.00805	0.00842	CcSEcCtD
Betaxolol—Hypokalaemia—Varenicline—nicotine dependence	0.00773	0.00809	CcSEcCtD
Betaxolol—Breast disorder—Varenicline—nicotine dependence	0.00768	0.00803	CcSEcCtD
Betaxolol—Cramp muscle—Varenicline—nicotine dependence	0.00765	0.008	CcSEcCtD
Betaxolol—Nasopharyngitis—Varenicline—nicotine dependence	0.0076	0.00795	CcSEcCtD
Betaxolol—Dysphagia—Varenicline—nicotine dependence	0.00734	0.00768	CcSEcCtD
Betaxolol—Asthma—Varenicline—nicotine dependence	0.00734	0.00768	CcSEcCtD
Betaxolol—Angina pectoris—Varenicline—nicotine dependence	0.00715	0.00748	CcSEcCtD
Betaxolol—Bronchitis—Varenicline—nicotine dependence	0.00706	0.00739	CcSEcCtD
Betaxolol—Erectile dysfunction—Varenicline—nicotine dependence	0.00676	0.00707	CcSEcCtD
Betaxolol—Weight increased—Varenicline—nicotine dependence	0.00668	0.00699	CcSEcCtD
Betaxolol—Hyperglycaemia—Varenicline—nicotine dependence	0.00662	0.00693	CcSEcCtD
Betaxolol—Infestation—Varenicline—nicotine dependence	0.00655	0.00685	CcSEcCtD
Betaxolol—Infestation NOS—Varenicline—nicotine dependence	0.00655	0.00685	CcSEcCtD
Betaxolol—Depression—Varenicline—nicotine dependence	0.00653	0.00683	CcSEcCtD
Betaxolol—Acute coronary syndrome—Varenicline—nicotine dependence	0.00645	0.00675	CcSEcCtD
Betaxolol—Myocardial infarction—Varenicline—nicotine dependence	0.00642	0.00671	CcSEcCtD
Betaxolol—Stomatitis—Varenicline—nicotine dependence	0.00638	0.00668	CcSEcCtD
Betaxolol—Conjunctivitis—Varenicline—nicotine dependence	0.00636	0.00666	CcSEcCtD
Betaxolol—Epistaxis—Varenicline—nicotine dependence	0.00618	0.00646	CcSEcCtD
Betaxolol—Sinusitis—Varenicline—nicotine dependence	0.00614	0.00643	CcSEcCtD
Betaxolol—Bradycardia—Varenicline—nicotine dependence	0.00598	0.00626	CcSEcCtD
Betaxolol—Hypoaesthesia—Varenicline—nicotine dependence	0.00585	0.00612	CcSEcCtD
Betaxolol—Hallucination—Varenicline—nicotine dependence	0.00585	0.00612	CcSEcCtD
Betaxolol—Visual impairment—Varenicline—nicotine dependence	0.00566	0.00592	CcSEcCtD
Betaxolol—Eye disorder—Varenicline—nicotine dependence	0.00549	0.00575	CcSEcCtD
Betaxolol—Tinnitus—Varenicline—nicotine dependence	0.00548	0.00573	CcSEcCtD
Betaxolol—Cardiac disorder—Varenicline—nicotine dependence	0.00546	0.00571	CcSEcCtD
Betaxolol—Angiopathy—Varenicline—nicotine dependence	0.00533	0.00558	CcSEcCtD
Betaxolol—Immune system disorder—Varenicline—nicotine dependence	0.00531	0.00555	CcSEcCtD
Betaxolol—Mediastinal disorder—Varenicline—nicotine dependence	0.0053	0.00554	CcSEcCtD
Betaxolol—Chills—Varenicline—nicotine dependence	0.00527	0.00552	CcSEcCtD
Betaxolol—Arrhythmia—Varenicline—nicotine dependence	0.00525	0.00549	CcSEcCtD
Betaxolol—Mental disorder—Varenicline—nicotine dependence	0.00515	0.00539	CcSEcCtD
Betaxolol—Malnutrition—Varenicline—nicotine dependence	0.00512	0.00535	CcSEcCtD
Betaxolol—Erythema—Varenicline—nicotine dependence	0.00512	0.00535	CcSEcCtD
Betaxolol—Dysgeusia—Varenicline—nicotine dependence	0.00501	0.00524	CcSEcCtD
Betaxolol—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00492	0.112	CbGpPWpGaD
Betaxolol—Muscle spasms—Varenicline—nicotine dependence	0.00492	0.00515	CcSEcCtD
Betaxolol—Vision blurred—Varenicline—nicotine dependence	0.00482	0.00504	CcSEcCtD
Betaxolol—Tremor—Varenicline—nicotine dependence	0.00479	0.00501	CcSEcCtD
Betaxolol—Ill-defined disorder—Varenicline—nicotine dependence	0.00475	0.00497	CcSEcCtD
Betaxolol—Anaemia—Varenicline—nicotine dependence	0.00473	0.00495	CcSEcCtD
Betaxolol—Malaise—Varenicline—nicotine dependence	0.00461	0.00483	CcSEcCtD
Betaxolol—Vertigo—Varenicline—nicotine dependence	0.0046	0.00481	CcSEcCtD
Betaxolol—Syncope—Varenicline—nicotine dependence	0.00459	0.0048	CcSEcCtD
Betaxolol—Palpitations—Varenicline—nicotine dependence	0.00452	0.00473	CcSEcCtD
Betaxolol—Loss of consciousness—Varenicline—nicotine dependence	0.0045	0.0047	CcSEcCtD
Betaxolol—Cough—Varenicline—nicotine dependence	0.00447	0.00467	CcSEcCtD
Betaxolol—Chest pain—Varenicline—nicotine dependence	0.00436	0.00456	CcSEcCtD
Betaxolol—Myalgia—Varenicline—nicotine dependence	0.00436	0.00456	CcSEcCtD
Betaxolol—Arthralgia—Varenicline—nicotine dependence	0.00436	0.00456	CcSEcCtD
Betaxolol—Anxiety—Varenicline—nicotine dependence	0.00434	0.00454	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00433	0.00452	CcSEcCtD
Betaxolol—Discomfort—Varenicline—nicotine dependence	0.0043	0.0045	CcSEcCtD
Betaxolol—Dry mouth—Varenicline—nicotine dependence	0.00426	0.00446	CcSEcCtD
Betaxolol—Oedema—Varenicline—nicotine dependence	0.00418	0.00437	CcSEcCtD
Betaxolol—Infection—Varenicline—nicotine dependence	0.00415	0.00434	CcSEcCtD
Betaxolol—Shock—Varenicline—nicotine dependence	0.00411	0.0043	CcSEcCtD
Betaxolol—Nervous system disorder—Varenicline—nicotine dependence	0.0041	0.00428	CcSEcCtD
Betaxolol—Thrombocytopenia—Varenicline—nicotine dependence	0.00409	0.00428	CcSEcCtD
Betaxolol—Tachycardia—Varenicline—nicotine dependence	0.00408	0.00426	CcSEcCtD
Betaxolol—Skin disorder—Varenicline—nicotine dependence	0.00406	0.00424	CcSEcCtD
Betaxolol—Hyperhidrosis—Varenicline—nicotine dependence	0.00404	0.00422	CcSEcCtD
Betaxolol—Anorexia—Varenicline—nicotine dependence	0.00398	0.00416	CcSEcCtD
Betaxolol—Hypotension—Varenicline—nicotine dependence	0.0039	0.00408	CcSEcCtD
Betaxolol—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00384	0.0875	CbGpPWpGaD
Betaxolol—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0038	0.00398	CcSEcCtD
Betaxolol—Insomnia—Varenicline—nicotine dependence	0.00378	0.00395	CcSEcCtD
Betaxolol—Dyspnoea—Varenicline—nicotine dependence	0.00372	0.00389	CcSEcCtD
Betaxolol—Dyspepsia—Varenicline—nicotine dependence	0.00368	0.00384	CcSEcCtD
Betaxolol—Decreased appetite—Varenicline—nicotine dependence	0.00363	0.0038	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00361	0.00377	CcSEcCtD
Betaxolol—Fatigue—Varenicline—nicotine dependence	0.0036	0.00377	CcSEcCtD
Betaxolol—Constipation—Varenicline—nicotine dependence	0.00357	0.00374	CcSEcCtD
Betaxolol—Pain—Varenicline—nicotine dependence	0.00357	0.00374	CcSEcCtD
Betaxolol—Feeling abnormal—Varenicline—nicotine dependence	0.00344	0.0036	CcSEcCtD
Betaxolol—Urticaria—Varenicline—nicotine dependence	0.00332	0.00347	CcSEcCtD
Betaxolol—Body temperature increased—Varenicline—nicotine dependence	0.0033	0.00345	CcSEcCtD
Betaxolol—Hypersensitivity—Varenicline—nicotine dependence	0.00308	0.00322	CcSEcCtD
Betaxolol—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00305	0.0695	CbGpPWpGaD
Betaxolol—Asthenia—Varenicline—nicotine dependence	0.003	0.00313	CcSEcCtD
Betaxolol—Pruritus—Varenicline—nicotine dependence	0.00295	0.00309	CcSEcCtD
Betaxolol—Diarrhoea—Varenicline—nicotine dependence	0.00286	0.00299	CcSEcCtD
Betaxolol—Dizziness—Varenicline—nicotine dependence	0.00276	0.00289	CcSEcCtD
Betaxolol—Vomiting—Varenicline—nicotine dependence	0.00266	0.00278	CcSEcCtD
Betaxolol—Rash—Varenicline—nicotine dependence	0.00263	0.00275	CcSEcCtD
Betaxolol—Dermatitis—Varenicline—nicotine dependence	0.00263	0.00275	CcSEcCtD
Betaxolol—Headache—Varenicline—nicotine dependence	0.00262	0.00274	CcSEcCtD
Betaxolol—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00259	0.0589	CbGpPWpGaD
Betaxolol—Nausea—Varenicline—nicotine dependence	0.00248	0.00259	CcSEcCtD
Betaxolol—ADRB1—Monoamine GPCRs—DRD2—nicotine dependence	0.00197	0.045	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD2—nicotine dependence	0.00193	0.044	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00166	0.0378	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00162	0.037	CbGpPWpGaD
Betaxolol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00127	0.0289	CbGpPWpGaD
Betaxolol—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00125	0.0285	CbGpPWpGaD
Betaxolol—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00107	0.0245	CbGpPWpGaD
Betaxolol—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00106	0.0241	CbGpPWpGaD
Betaxolol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00103	0.0234	CbGpPWpGaD
Betaxolol—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00087	0.0198	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000816	0.0186	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—TAS2R16—nicotine dependence	0.000798	0.0182	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000579	0.0132	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000546	0.0124	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000538	0.0123	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000527	0.012	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000515	0.0117	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000491	0.0112	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000462	0.0105	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000461	0.0105	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000456	0.0104	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000451	0.0103	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000451	0.0103	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000442	0.0101	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000419	0.00953	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000409	0.00932	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000381	0.00868	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000373	0.00849	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—FGD1—nicotine dependence	0.000362	0.00824	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—FGD1—nicotine dependence	0.000354	0.00806	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—OPRM1—nicotine dependence	0.000344	0.00783	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—OPRM1—nicotine dependence	0.000336	0.00766	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—FGD1—nicotine dependence	0.000328	0.00748	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000326	0.00743	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—FGD1—nicotine dependence	0.000321	0.00732	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000319	0.00727	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD2—nicotine dependence	0.000249	0.00566	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TAS2R16—nicotine dependence	0.000247	0.00563	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD2—nicotine dependence	0.000243	0.00554	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TAS2R16—nicotine dependence	0.000242	0.00551	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000194	0.00442	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGD1—nicotine dependence	0.000194	0.00442	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—OPRM1—nicotine dependence	0.00019	0.00433	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGD1—nicotine dependence	0.00019	0.00432	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—OPRM1—nicotine dependence	0.000176	0.00402	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—OPRM1—nicotine dependence	0.000173	0.00393	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKR1B10—nicotine dependence	0.000171	0.0039	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKR1B10—nicotine dependence	0.000168	0.00382	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD2—nicotine dependence	0.00014	0.0032	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD2—nicotine dependence	0.000137	0.00313	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD2—nicotine dependence	0.000128	0.00291	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD2—nicotine dependence	0.000125	0.00284	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—WASF2—nicotine dependence	0.000121	0.00275	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—WASF2—nicotine dependence	0.000118	0.00269	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—WASF1—nicotine dependence	0.000116	0.00264	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—WASF1—nicotine dependence	0.000113	0.00258	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—OPRM1—nicotine dependence	0.000104	0.00237	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—OPRM1—nicotine dependence	0.000102	0.00232	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP2A7—nicotine dependence	9.33e-05	0.00213	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2A7—nicotine dependence	7.91e-05	0.0018	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD2—nicotine dependence	7.54e-05	0.00172	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD2—nicotine dependence	7.37e-05	0.00168	CbGpPWpGaD
